STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACRV
  4. [Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity

Acrivon Therapeutics insiders report tax share withholding on Form 4

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. insiders reported routine tax‑related share transactions. On 11/14/2025, President and CEO Dr. Peter Blume-Jensen had 59,765 shares of common stock withheld by the company at $2.24 per share to cover mandatory tax withholding upon vesting of restricted stock units, leaving him with 2,066,675 shares held directly. On the same date, 490 shares were similarly withheld at $2.24 per share from holdings reported as indirect, leaving 314,706 shares held indirectly. The filing notes that Dr. Blume-Jensen and co-founder and EVP – Business Operations Dr. Kristina Masson are spouses and each disclaims beneficial ownership of the other’s securities except to the extent of their pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Blume-Jensen Peter, Masson Kristina
Role President and CEO | EVP - Business Operations
Type Security Shares Price Value
Tax Withholding Common Stock 59,765 $2.24 $134K
Tax Withholding Common Stock 490 $2.24 $1K
Holdings After Transaction: Common Stock — 2,066,675 shares (Direct); Common Stock — 314,706 shares (Indirect, See Footnote)
Footnotes (1)
  1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blume-Jensen Peter
(Last) (First) (Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100
(Street)
WATERTOWN MA 02472
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/14/2025 F(1) 59,765 D $2.24 2,066,675 D(2)
Common Stock 11/14/2025 F(1) 490 D $2.24 314,706 I See Footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Blume-Jensen Peter
(Last) (First) (Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100
(Street)
WATERTOWN MA 02472
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
1. Name and Address of Reporting Person*
Masson Kristina
(Last) (First) (Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100
(Street)
WATERTOWN MA 02472
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director 10% Owner
X Officer (give title below) Other (specify below)
EVP - Business Operations
Explanation of Responses:
1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen 11/18/2025
/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson 11/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Acrivon Therapeutics (ACRV) report on this Form 4?

The Form 4 reports that on 11/14/2025, President and CEO Dr. Peter Blume-Jensen had 59,765 common shares and an additional 490 common shares withheld by Acrivon Therapeutics at $2.24 per share to satisfy mandatory tax withholding upon vesting of restricted stock units.

Why were Acrivon Therapeutics (ACRV) shares withheld from the insiders?

According to the explanation, the shares were withheld by the issuer to satisfy mandatory tax withholding requirements that arose upon the vesting of restricted stock units, a common method for covering tax obligations on equity awards.

How many Acrivon Therapeutics (ACRV) shares does the CEO hold after these transactions?

After the reported withholding on 11/14/2025, President and CEO Dr. Peter Blume-Jensen beneficially owns 2,066,675 shares of common stock directly, in addition to indirect holdings described in the filing.

What are the indirect Acrivon Therapeutics (ACRV) holdings reported in this Form 4?

Following the 490-share withholding at $2.24 per share, the Form 4 shows 314,706 common shares held indirectly, with the narrative explaining cross-ownership between Dr. Peter Blume-Jensen and co-founder and EVP – Business Operations Dr. Kristina Masson as spouses.

How are the relationships between Acrivon Therapeutics insiders described in the Form 4?

The filing states that Dr. Peter Blume-Jensen is President, CEO and a director and Dr. Kristina Masson is co-founder and EVP – Business Operations and a director. It notes they are spouses and that each disclaims beneficial ownership of the other’s securities except to the extent of their pecuniary interest.

Does this Acrivon Therapeutics (ACRV) Form 4 indicate an open-market sale by insiders?

No. The transaction code is F, and the explanation clarifies that the shares were withheld by the issuer to satisfy mandatory tax withholding upon restricted stock unit vesting, rather than discretionary open-market sales.